← All trials
NCT04425291
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 28, 2020
- Primary completion
- Dec 28, 2021
- Completion date
- Dec 28, 2021
- First posted
- Jun 12, 2020
- Last posted
- Jun 12, 2020
- Enrollment
- 1680
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Shanghai Bovax Biotechnology Co., Ltd.Lead sponsor
- Shanghai Bovax Biotechnology Co., Ltd.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.